Citius Pharmaceuticals, Inc. (CTXR)

NCM – Real vaqt narxi. Valyuta: USD

0.76

+0.04 (6.25%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

0.75

-0.02 (-2.00%)

Bozordan keyin: Aug 12, 2026, 5:14 PM EDT

12.08.2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.

05.08.2026

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product's commercial launch.

Videolar

No Data

There is no data to display

Press-relizlar

12.08.2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

05.08.2026

Citius Pharmaceuticals, Inc. (CTXR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Citius Pharmaceuticals, Inc. (CTXR)

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videolar

No Data

Press-relizlar

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videolar

No Data

Press-relizlar

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Search stocks

Citius Pharmaceuticals, Inc. (CTXR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Citius Pharmaceuticals, Inc. (CTXR)

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videolar

No Data

Press-relizlar

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videolar

No Data

Press-relizlar

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment